• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Pharma

BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial

byUsamah BhaiduandFlaviu Trifoi
September 3, 2024
in Pharma
Reading Time: 2 mins read
Adding sargramostim to ipilimumab may improve survival in advanced melanoma
Share on FacebookShare on TwitterShare on LinkedIn
  1. Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma compared to therapy with cemiplimab alone.
  2. BNT111 was well tolerated by participants.

The Latest

In a collaboration between BioNTech and Regeneron, researchers performed an open-label, randomized phase 2 clinical trial evaluating the efficacy of BioNTech’s BNT111 and Regeneron’s anti-PD-1 inhibitor cemiplimab in the treatment of inoperable or advanced-stage anti-PD-1 inhibitor-resistant melanoma. The study showed that patients taking the combination BNT111/cemiplimab experienced a significantly improved overall response rate and the drug was well tolerated. Next, researchers hope to continue working on the secondary endpoints in this trial and present their full results shortly.

Physician’s Perspective

Melanoma is a type of skin cancer and is the most common cause of skin cancer-related deaths. Repeated exposure to ultraviolet radiation (from the sun or tanning beds) tends to be the most common cause of melanoma. The immune system attempts to fight cancer cells by expressing a protein on their surface called PD-1. PD-1 on T cells binds to PD ligand (PDL) on normal host cells to prevent their degradation. Melanoma cells exploit this checkpoint by expressing their own PDLs which deceive T cells into perceiving the cancerous cells as normal cells. In advanced cancers, one mode of treatment uses anti-PD-1 antibodies to prevent melanoma from using this exploitation. However, some advanced forms of melanoma are resistant to anti-PD-1 antibody treatment. BioNTech’s BNT111 hopes to improve the treatment of anti-PD1 inhibitor-resistant melanoma by targeting this mechanism.

Molecular Target of Therapy

Most melanoma cells express specific antigens on their surface which can be recognized by the immune system as foreign and marked for destruction. BNT111 is an mRNA-based treatment delivered to melanoma cells causing the production of such specific antigens on their surface. This makes cancer cells recognizable to the immune system. Ultimately, BNT111 boosts the immune response towards melanoma and increases the efficacy of cemiplimab when the two are used in combination.

RELATED REPORTS

Artificial intelligence matches dermatologists in melanoma diagnosis

2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th,  2025]

Company History

BioNTech is a biotechnology company based in Germany that specializes in next-generation immunotherapy. The company became well known recently for its collaborative effort with Pfizer in the development of the mRNA-based covid-19 vaccine. Presently, the company has over 30 candidates in various stages of clinical research. These are mRNA-based candidates for the treatment of cancers ranging from lung to colorectal to pancreatic, as well as other diseases like tuberculosis and malaria.

 

Further reading: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-positive-topline-phase-2-results-mrna

FDA approvedFor melanoma: Tudriqev (vusolimogene oderparepvec-wtpg), Aug 6, 2026→

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: biontechbnt111cemiplimabmelanoma
Previous Post

Individualized acupuncture not associated with significant improvements in chronic neck pain

Next Post

#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

RelatedReports

Melanoma collage: a magnifying glass over an even mole and an uneven one on skin, with a sun hat and sunglasses
AI Roundup

Artificial intelligence matches dermatologists in melanoma diagnosis

September 15, 2025
2 Minute Medicine AI Roundup editorial illustration
AI Roundup

2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th,  2025]

September 25, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

August 28, 2025
Blood tests collage: a tray of capped sample tubes lying flat, an open benchtop centrifuge and a pipette
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
Next Post
#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

Intravenous amino acids decrease acute kidney injury following cardiac surgery

Healthcare worker burnout collage: a tired male nurse in scrubs with his mask lowered beside a coronavirus particle

Oseltamivir and peramivir may reduce length-of-hospital-stay in patients with severe influenza

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.